By Stephen Nakrosis
Onconetix on Thursday said it named its interim Chief Financial Officer, Karina Fedasz, as interim Chief Executive Officer, effective immediately.
Also on Thursday, the biotechnology company said James Sapirstein resigned as executive chairman and as a member of the board.
Fedasz has helped companies raise capital, model and forecast business, manage cash flow and conduct mergers and acquisitions for more than two decades, Onconetix said. She has been interim CFO of Onconetix since June 2024. Before that, she worked with various clients, including a not-for-profit and an early-stage artificial intelligence and data-driven health and wellness tracker.
Prior to that, Fedasz was head of business development for Evofem Biosciences, and also served in various positions of increasing responsibility, including CFO, at IDW Media Holdings, Onconetix said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
April 03, 2025 18:34 ET (22:34 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。